In studies with postmortem validation, the discriminatory accuracies between Aβ + AD and Aβ- non-AD cases were as high as > 90%, with plasma p-tau being able to further distinguish between non-AD cases with or without concomitant AD pathology [32, 42, 45, 46, 48, 60, 61, 86]. The gene discussed is MAPT; the disease is Alzheimer disease.